TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Integrativ Biomedicin Öckerman AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
37
|
46
|
42 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
14
|
20
|
-3 |
| EBITDA |
5
|
11
|
-12 |
| Total assets |
55
|
66
|
64 |
| Current assets |
53
|
64
|
61 |
| Current liabilities |
3
|
4
|
2 |
| Equity capital |
51
|
61
|
61 |
| - share capital |
9
|
9
|
9 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
92.4%
|
95.3% |
| Turnover per employee |
37
|
46
|
42 |
| Profit as a percentage of turnover |
37.8%
|
43.5%
|
-7.1% |
| Return on assets (ROA) |
25.5%
|
30.3%
|
-4.7% |
| Current ratio |
1766.7%
|
1600%
|
3050.0% |
| Return on equity (ROE) |
27.5%
|
32.8%
|
-4.9% |
| Change turnover |
-7
|
4
|
-2 |
| Change turnover % |
-17%
|
9%
|
-4% |
| Chg. No. of employees |
0
|
0
|
1 |
| Chg. No. of employees % |
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.